Please find attached herewith Intimation about US FDA Inspection at Company'' s manufacturing facility located at Amaliya, Daman.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
US FDA conducted a routine inspection at Alkem Laboratories' manufacturing facility in Amaliya, Daman from April 20 to May 1, 2026. At the end of the inspection, the company received Form 483 with seven observations, which are官方 FDA forms documenting potential violations found during the inspection. The company has stated it will address all seven observations within the stipulated timeframe. Form 483 observations indicate compliance issues that require corrective action before the facility can continue or expand its US market operations without regulatory risk.
Form 483 observations are a compliance concern for pharmaceutical exporters to the US market. If not resolved satisfactorily, this could lead to warning letters or import alerts, potentially affecting the company's US revenue. Shareholders should monitor how quickly and effectively the company addresses these observations.